RenovoRx Inc
RNXT
NASDAQ
Biotechnology
$1.40
USD
+0.14 (+11.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $56.77M
Volume 1.0M
Revenue
$1.49M
TTM
+520.4%
YoY
Gross Margin
79%
TTM
+29.4%
YoY
Net Income
$-12.27M
TTM
-20.8%
YoY
Operating Cash Flow
$-11.30M
TTM
-9.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 0.4 | 0.3 | 0.2 | 0.6 |
YoY Growth | — | — | — | +453.5% | +185.8% |
Cost of Revenue | 0.1 | 0.2 | 0.1 | 0.0 | 0.1 |
Gross Profit | 0.1 | 0.3 | 0.2 | 0.2 | 0.5 |
Selling, General & Administrative | 1.6 | 1.5 | 1.7 | 2.2 | 2.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.2 | 2.9 | 3.4 | 3.7 | 3.9 |
Operating Income | -3.1 | -2.7 | -3.2 | -3.5 | -3.5 |
EBITDA | -3.1 | -2.7 | -3.2 | -3.5 | -3.5 |
Other Income / Expense | 0.6 | -0.4 | 0.2 | 0.5 | -0.1 |
Total Other Income / Expense | 0.7 | -0.2 | 0.3 | 0.6 | -0.1 |
Income Before Income Taxes | -2.4 | -2.9 | -2.9 | -2.9 | -3.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.4 | -2.9 | -2.9 | -2.9 | -3.5 |
Consolidated Net Income / Loss | -2.4 | -2.9 | -2.9 | -2.9 | -3.5 |
Net Income Attributable to Common Shareholders | -2.4 | -2.9 | -2.9 | -2.9 | -3.5 |
Basic EPS | -$0.08 | -$0.08 | -$0.08 | -$0.08 | -$0.09 |
Diluted EPS | -$0.08 | -$0.08 | -$0.08 | -$0.08 | -$0.09 |
Basic Shares Outstanding | 31.4M | 36.6M | 36.6M | 36.7M | 38.0M |
Diluted Shares Outstanding | 31.4M | 36.6M | 36.6M | 36.7M | 38.0M |